First Department of Internal Medicine, Kagawa Univesity, 1750-1 Miki-cho, Kita-gun, Kagawa prefecture 761-0793, Japan.
World J Gastroenterol. 2011 Nov 7;17(41):4632-4. doi: 10.3748/wjg.v17.i41.4632.
Adjuvant chemotherapy by S-1 following gastrectomy is considered standard treatment in Japan. Analysis of follow-up data have proved the efficacy of S-1 administration, and that hematological adverse events were relatively rare. Pyrimidine anti-metabolites, including S-1, have shown relatively lower risks for secondary hematological malignancies in comparison to alkylating agents and topoisomerase-II inhibitors. We here report a case of therapy-related leukemia after S-1 administration. A patient who had received S-1as the sole adjuvant chemotherapy was diagnosed with acute erythroid leukemia. To the best of our knowledge, our patient represents the first report of S-1 induced acute leukemia.
在日本，胃切除术后进行 S-1 辅助化疗被认为是标准治疗。随访数据的分析证明了 S-1 给药的疗效，且血液学不良事件相对较少。与烷化剂和拓扑异构酶-II 抑制剂相比，包括 S-1 在内的嘧啶抗代谢物在继发性血液系统恶性肿瘤方面的风险相对较低。我们在此报告一例 S-1 给药后发生的治疗相关性白血病。一名接受 S-1 作为唯一辅助化疗的患者被诊断为急性红细胞白血病。据我们所知，我们的患者是首例 S-1 诱导的急性白血病报告。
